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A JOINT meeting between the European Commission and the 
Karolinska Institute was held in Stockholm in the Autumn of 
1995. The aim of the meeting was to highlight cancer research 
projects supported by the European Commission. Basic sci- 
ence and clinical studies were presented, and the idea was 
to delineate important areas for support by the European 
Commission in the future. Here we have tried to highlight 
some of the topics, well aware of the fact that many that are 
not mentioned may be as important as those mentioned in 
this overview. 
In terms of basic science, the role of viruses and genes were 
discussed. A presentation by Dumont (Brussels) focused on 
the control of proliferation and differentiation of normal and 
malignant thyroid cells in the search for new protooncogenes. 
Thyroglobulin, thyroperoxidase and TSH receptors as differ- 
entiation markers were shown to be decreased in various 
human adenocarcinomas and almost absent in anaplastic car- 
cinomas. These markers were used for diagnosis and differen- 
tial screening of cDNA libraries from thyroids. This allowed 
the identification of several unknown clones involved in cell 
regulation. Systematic screening of hereditary medullar thy- 
roid carcinoma was performed in eight families with multiple 
endocrine neoplasia. Ret protooncogene point mutations were 
found in all affected members of each family. 
Plachov’s (Miinster) presentation focused on the role of the 
human PAX2 and PAX8 transcription factors. These genes 
are expressed in the embryonic kidney, the developing CNS 
and the adult thyroid. Furthermore, overexpression of both 
PAX2 and PAX8 was demonstrated in Wilms’ tumours that 
originate from human embryonic kidney. The function of the 
wild type and mutated versions of these genes was further 
analysed in transfection experiments. PAX8 appears to be part 
of the CAMP signalling pathway and mediates TSH dependent 
gene activation of thyroid cells. 
Poupon (Paris) analysed Homeobox-containing genes and 
showed that malignant transformation is associated with alt- 
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ered HOX gene expression in kidney and colon cancer cells. 
HOX gene expression was further analysed in primary and 
metastatic human small cell cancers (SCLS) by Northern 
blotting. The combined results were in favour of the involve- 
ment of HOX genes in tumour progression. 
Lower animal species can be useful genetic models for 
cancer research and tumour suppression (Mechler, 
Heidelberg). Genetic analysis of Drosophila has revealed that 
gene inactivation can lead to tumorigenesis in specific tissues 
during the fruit fly’s development. Five tumour suppressor 
genes, controlling growth of haematopoietic organs, were 
cloned and analysed. Some of these genes display homologies 
with nuclear carrier proteins found in Xenopus (importin 60), 
yeast (SRPl), or humans (RCHI). Analysis of the oho 23 gene 
showed that this gene encodes the S21 ribosomal protein, 
whose absence may cause tissue specific neoplasia, a hitherto 
unknown mechanism of tumorigenesis. 
Invading foreign DNA or RNA molecules are also involved 
in tumour formation (e.g. HBV, HCV, HPV, EBV, HIV). 
Epidemiological studies by Brechot (Paris) revealed a very 
close relation betwen Hepatitis B virus (HBV) and Hepatitis 
C (HCV) infection and primary liver cancer. This was based 
on serum and liver samples obtained from patients with pri- 
mary liver cancer in different European countries. 
GraessmannLevrero (Berlin/Rome) analysed in more detail 
the function of the HBV-X protein in vitro (cell culture) and 
in viva (transgenic animals). Microinjection and transfection 
experiments confirmed that the X-protein is mainly found in 
the cytoplasm of the recipient cells, and intranuclear localis- 
ation of the X-protein was not demonstrable. Furthermore, 
tumour revertant rat cells (REV), which still synthesise the 
wt SV-T antigen, but not the grant-parental cells (RJZF52), 
became fully transformed again by the HBV-X protein. This 
indicates that expression of the X-protein per se is not sufficient 
for maximal cell transformation, but that the X-protein may 
have a tumour-promoter function. Transgenic animals that 
express the X-protein in mammary gland cells during late 
pregnancy and lactation exhibited an altered gland mor- 
phology. 
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The human T-cell leukaemia virus type I (HTLV-I) is 
causally associated with adult T-cell leukaemia/lymphoma 
(ATLL). From HTLV-I infected patients, only 5% develop 
ATLL. It is unknown whether HTLV-II, which is commonly 
found in association with HIV-I in Europe, contributes to the 
morbidity and mortality of ATLL patients. A network was 
established (Weber, London) for the diagnosis of HTLV-I/II 
infection and more than 4 million blood samples were col- 
lected in different European countries. 
conditioning, graft-versus-host disease prophylaxis (without 
T-cell depletion), short interval between diagnosis and BMT, 
and young age are important factors for outcome. 
That viruses are not only associated with tumour formation 
but may also cause oncosuppression was further discussed 
by Rommelaere (Heidelberg). It was demonstrated that the 
preferential killing of tumour cells by the parvoviruses is in 
part due to the greater extent of virus replication in transfor- 
med cells, compared to normal cells. The P4 promoter 
directed NS/Rep proteins are not only essential for virus 
replication, but these proteins are also cytotoxic. 
Studies by P.G. Pelicci and associates on acute promyelo- 
cytic leukaemia revealed that transfection-induced expression 
of the APLspecific PMLRARA fusion protein blocks differ- 
entiation and inhibits programmed cell death, but makes the 
cells sensitive to retinoic acid (RA). The PML-RARA fusion 
protein appears to contain most functional characteristics 
of the normal PML and RARA proteins. Apparently, the 
combined functional characteristics are responsible for the 
differentiation block and oncogenic potential on the one hand 
and for the sensitivity to RA-induced differentiation on the 
other hand. 
Progress reports were presented concerning 13 Concerted 
Actions on childhood cancers or haematological disorders. 
The search for the mol!ecular defect in Funconi anemia (FA) 
by E. Gluckrnan and associates has revealed that at least 
five complementation groups exist (based on fusion of EBV 
transformed cell lines). Complementation group A (FAA) is 
the largest group. Genetic linkage studies have demonstrated 
that the affected gene in FAA is located on 16q24.1-24.3. The 
affected gene in complementation group C (F/K) has been 
cloned and so far eight different mutations have been ident- 
ified. Geographic clustering of FA subtypes has been found in 
Europe, e.g. the FAA gene is most frequently involved in 
Germany, whereas in The Netherlands, FAC gene aberrations 
are more frequently found. Interestingly, all the studied FAC 
patients in The Netherlands had the same mutations. The 
first prenatal diagnosis of a (healthy) dizygotic twin-preg- 
nancy, being a carrier of one mutated FAC allele, was 
reported. 
The study by B. Van Camp and colleagues investigated the 
immunopathogenesis of multiple myeloma. Molecular studies 
of immunoglobulin (Ig) gene rearrangements have demon- 
strated that multiple myeloma patients have peripheral blood 
monoclonal B cells with identical hypermutated V-D-J gene 
rearrangements, but without Ig class switch. Based on these 
findings, it is assumed that the multiple myeloma cells orig- 
inate from germinal centre B-cells, which migrate from the 
lymph node to the bone marrow, where they differentiate into 
mature tumour cells, due to interaction with marrow stroma. 
H. Jtirgens and associates utilised a PCR-based staging in 
Ewing’s sarcoma. The characteristic molecular aberrations in 
Ewing’s sarcoma involve the EWS gene on chromosome 22 
and concern t(l1;22) in about 90% of cases and t(21;22) in 
about 5% of cases. Both aberrations are detectable by PCR 
analysis and were used for precise staging, thereby allowing 
better discrimination between localised tumour and metastatic 
disease in bone marrow and/or blood. The PCR studies were 
also used for detection of residual disease during or after 
treatment in patients with disseminated Ewing’s sarcoma. 
L.M. Fischer and associates tried to unravel the molecular 
basis of anticancer drug action on topoisomerase II (top0 II), 
especially the role of the ternary DNA complex in drug 
sensitivity and resistance. Information from the project might 
lead to design of selective more potent drugs and the develop- 
ment of strategies to circumvent cellular resistance. Topo II is 
an important target for anticancer agents, such as anthracy- 
clines. Topo II catalysed chromosome segregation by double 
strand break mechanisms. Two types of topo II exist in man: 
topo IIa (gene on chromosome 17q2 1 - 11) is expressed during 
G2 and M phases of the cell cycle, while topo IIB (gene on 
chromosomes 3~24) exhibits continuous expression. 
A. Hagemeijer and colleagues tried to bridge the gap 
between research units and diagnostic laboratories working 
on molecular cytogenetics in haematological malignancies. 
Special attention is paid to multi-target translocations such 
as 1 lq23 aberrations (MLL gene) and 12~13 (TEL gene). 
Important aims are the design of powerful probes for fluor- 
escence in situ hybridisation (FISH), such as for BCR, AX, 
MLL, ETO, etc., and the development of multiplex PCR for 
rapid detection of chromosome aberrations. 
G. Gahrton and colleagues acted in several directions to Detection of minimal residual disease (MRD) in acute 
optimise bone marrow transplantation with unrelated donors. leukaemia patients is essential to obtain insight in the effective- 
Bone marrow transplantation (BMT) has proven to be an ness of cytostatic treatment. Such information can be used 
efficient treatment in many haematological malignancies and to determine whether MRD detection can be applied for 
is also becoming important in the treatment of solid tumours. stratification/adaptation of treatment protocols. J.F. San 
In 1994, approximately 9000 marrow transplantations have Miguel and colleagues tried to develop and standardise 
been performed in Europe, mainly for leukaemia, malignant methods for MRD detection. Two main types of techniques 
lymphoma and solid tumours. In two-thirds of cases, it con- were used: (1) immunological marker analysis using multip- 
cerned autologous BMT and in one-third allogeneic BMT. arameter flow cytometry with triple antibody combinations; 
Most donors (about 2700) were HLA-matched siblings, but and (2) PCR analysis of leukaemia-specific sequences. The 
matched volunteers were used in increasing numbers-now participating centres for flow cytometric MRD detection now 
600. A European database of HLA-typed volunteer donors is use the same antibody panels and have agreed on the method- 
being built, and a registry of “Bone Marrow Donors World- ology for sample preparation techniques, data acquisition 
wide” now contains 2.7 million typed volunteers. Comparison and data analysis. The first results of the centres are highly 
of unrelated donor (UD)-BMT with identical sibling (ID)- comparable. Progress in the molecular MRD studies include 
BMT revealed that HLA-matching is extremely important for the central production of DNA probes and PCR primers 
results of UD-BMT to approach those of ID-BMT. UD- and their evaluation for detection of junctional regions of 
BMT studies in chronic myeloid leukaemia revealed that rearranged Ig and TcR genes as PCR targets. The develop- 
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ment of standardised primer sets for detection of chromosome 
aberrations is under investigation. 
One aim with the Stockholm meeting was to bridge from 
basic to clinical research. However, a number of obstacles 
were encountered in trying to obtain this goal. Two examples 
are provided to clarify the point. 
The first is based on the report by I?. Herdewijn (Leuven, 
Belgium) concerning the anticancer activity of antisense oli- 
gonucleotides targeted against mutated RAS. The limiting 
factors in the activity of such compounds are their instability 
and their poor cellular uptake. The authors therefore modified 
the structure of the oligonucleotides by making partially 
complementary duplexes to increase stability and by coupling 
the duplexes to a propanediol moiety to increase cellular 
uptake. This modified oligonucleotide was shown to be 400 
times more effective in inhibiting cancer cell growth in vitro 
than the unmodified one. It was also found to be effective in 
T&O in animal models after direct injection in the tumour 
mass. This compound could now be tested in human malig- 
nancies carrying appropriate mutations of RAS. 
However, in the academic field, the cost of running such a 
trial might be prohibitive. RAS mutations, as well as the 
antisense technology, are not patentable because they are in 
the public domain, and therefore no private company is willing 
to invest in clinical trials. This raised the more general issue of 
the funding of clinical trials with compounds that are promis- 
ing for the treatment of cancer but which, for economic 
reasons, are of no interest to private companies. These are 
cases in which public funding would be the most appropriate, 
and there the support of the European Community could be 
very helpful. 
The other example is related to the need for a co-ordinating 
structure at the European level for new types of clinical trials. 
Recent developments in tumour immunology allowed the 
identification, mainly by the group of T. Boon in Brussels, of 
the molecular nature of a number of human tumour antigens 
that are the targets of a cytolytic T cell response of the host 
against its own tumour cells. These antigens are presented to 
cytolytic T lymphocytes by HLA class I molecules, and consist 
of small peptides derived from proteins that are exclusively 
expressed in the tumour cells. Because of their tumour-speci- 
ficity, these antigens could constitute the basis of future cancer 
vaccines. Small pilot studies with such vaccines are under way 
in melanoma patients, and preliminary results seems very 
promising. If this is confirmed, the next step will be the 
running of large-scale multicentre trials. 
The organisation of large-scale multicentre trials is not easy 
because the recruitment of patients is based on very specific 
selection criteria: eligible patients have to express a given HLA 
molecule and their tumour must express the relevant antigen. 
Therefore, the patients have to be HLA-typed, and their 
tumours tested for the expression of the gene encoding the 
antigen by PCR on RNA extracted from the tumour. To 
organise such complex studies, there is a need for co-ordi- 
nation at the international level, which raised the more general 
issue of the need for a supranational structure that should be 
responsible for such co-ordination. In Europe, a structure like 
the EORTC would be well suited to this. In this vein, H. 
Zwierzina (Innsbruck) reported the recent creation within the 
EORTC of a new working group called “Biological Thera- 
peutics of Development Study Group”, which is devoted to 
the study of new treatments based on biological response 
modifiers in cancer. 
A related issue was raised by D. Gabel (Bremen, Germany) 
when he asked: “How to conduct clinical trials on European 
schemes rather than on National schemes”. This question 
referred to the huge differences in the national policies of the 
different European countries on clinical research and more 
particularly on the review process and insurance coverage. 
These differences definitely impede fruitful international col- 
laboration between European clinical researchers. To har- 
monise the different national policies, a solution would be to 
support a European co-ordinating organisation that would 
have the means to propose common guidelines on this matter. 
European countries differ not only in their policies on 
clinical research, but also in their efficiency in applying well- 
known cancer treatments, and this was clearly reflected in the 
results of a large epidemiological study called “Eurocare” 
reported by F. Berrino (Milan, Italy). This study, which was 
based on the cancer registries of 12 European countries, 
unmasked striking differences in the survival rates of cancer 
patients depending on the country in which they were treated. 
The origins of these differences are not yet clear and are 
presently being studied. Once again this highlights the need 
for translational research including education of physicians 
and optimal procedures to disseminate the results of high 
quality clinical trials. 
Also, there is currently an increasing number of clinicians 
involved in clinical research who face numerous obstacles such 
as cost of clinical research, workload, legal and administrative 
matters, lack of support from hospital directors and difficulties 
in obtaining adequate local data management. Less than 10% 
of medical doctors have ever participated in clinical trials and 
less than 5% of cancer patients are currently included in 
clinical trials. 
Therefore, support from the European Commission is 
important. As shown by the results of the projects, highlighted 
in this review, with moderate funding European cancer 
research can flourish. 
